Compare T & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | T | NVO |
|---|---|---|
| Founded | 1983 | 1923 |
| Country | United States | Denmark |
| Employees | 268000 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.8B | 199.4B |
| IPO Year | 2015 | 2001 |
| Metric | T | NVO |
|---|---|---|
| Price | $22.19 | $41.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 14 |
| Target Price | $27.59 | ★ $45.63 |
| AVG Volume (30 Days) | ★ 36.7M | 8.9M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.00% | 3.15% |
| EPS Growth | ★ 104.03 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $125,648,000,000.00 | N/A |
| Revenue This Year | $3.42 | $0.06 |
| Revenue Next Year | $0.01 | $1.32 |
| P/E Ratio | $16.62 | ★ $13.60 |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $19.89 | $35.12 |
| 52 Week High | $29.44 | $64.16 |
| Indicator | T | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 57.17 |
| Support Level | $22.20 | $41.05 |
| Resistance Level | $23.73 | $43.24 |
| Average True Range (ATR) | 0.44 | 0.83 |
| MACD | 0.21 | 0.25 |
| Stochastic Oscillator | 83.84 | 68.09 |
The wireless business contributes nearly 70% of AT&T's revenue. The company is the third-largest US wireless carrier, connecting 74 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 14% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential services, about 11% of revenue, primarily consist of in-home broadband internet access, serving 15 million customers. AT&T also has a sizable presence in Mexico, with 25 million wireless customers, but this business only accounts for 3% of revenue. The company recently sold its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.